Targeting the BAFF/APRIL cytokine network in multiple myeloma

Stephen A. Mihalcik, Diane F Jelinek

Research output: Chapter in Book/Report/Conference proceedingChapter

Abstract

The BAFF/APRIL cytokine network is intimately linked through three different receptors to the survival and fi tness of B lineage cells, from the first expression of a complete B cell receptor to their differentiation to memory B and plasma cells. The speci fi c, pervasive, and survival-linked nature of the relationship between B lineage cells and this cytokine network make it both a likely disease modi fi er and a tantalizing target for therapeutic intervention in humoral immune pathologies. Some current therapeutics directly targeting the BAFF/APRIL cytokine network have been developed and undergone clinical trials in the context of autoimmunity with some limited success. Despite a powerful rationale and a constantly deepening mechanistic understanding of the BAFF/APRIL cytokine network in normal and malignant plasma cells, trials of cytokine network-targeted therapeutics in multiple myeloma are still in their infancy and have shown only minor promise. There is signi fi cantly greater potential in inhibiting NF-kB, a downstream mediator of BAFF/APRIL signals.

Original languageEnglish (US)
Title of host publicationAdvances in Biology and Therapy of Multiple Myeloma: Volume 1: Basic Science
PublisherSpringer New York
Pages187-202
Number of pages16
ISBN (Print)9781461446668, 9781461446651
DOIs
StatePublished - Jan 1 2013

    Fingerprint

ASJC Scopus subject areas

  • Medicine(all)

Cite this

Mihalcik, S. A., & Jelinek, D. F. (2013). Targeting the BAFF/APRIL cytokine network in multiple myeloma. In Advances in Biology and Therapy of Multiple Myeloma: Volume 1: Basic Science (pp. 187-202). Springer New York. https://doi.org/10.1007/978-1-4614-4666-8_10